Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
Status:
Completed
Trial end date:
2010-04-14
Target enrollment:
Participant gender:
Summary
A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered
with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response
(RVR) i.e., undetectable hepatitis C virus [HCV] viral ribonucleic acid [RNA] at Week 4 in
participants with chronic HCV infection. The primary hypothesis was that the proportion of
participants in one or more of the Vaniprevir treatment groups achieving RVR would be greater
than the proportion of placebo participants achieving RVR when Vaniprevir and placebo were
co-administered with Peg-IFN/Ribavirin.